| Literature DB >> 34909671 |
Shailesh Bhosale1, Anoop Kumar1.
Abstract
Japanese encephalitis (JE) is one of the viral diseases affecting millions of peoples across the globe specifically developing countries. There is no specific treatment available, however, vaccines are available for its prevention. Unfortunately, available vaccines are not effective against all clinical isolates and are also associated with neurological complications in some individuals. We have screened the selected phytoconstituents of Andrographis paniculata against various targets of Japanese encephalitis virus (JEV) using Schrodinger suite 2019-3. Among all selected phytoconstituents, andrographolide has shown a good binding affinity towards NS3 protease as compared to NS3 helicase and NS5 Rdrp (RNA dependent RNA polymerase) of JEV. The molecular dynamics (MD) results have also shown good stability of andrographolide in the active site of NS3 protease. The absorption, distribution, metabolism, excretion, and toxicity (ADMET) analysis has also indicated a good pharmacokinetic and safety profile of andrographolide. Finally, the in-vitro target-based assay have confirmed the inhibitory potential of andrographolide against the NS3 protease of JEV. In conclusion, andrographolide could have the potential to develop as an antiviral agent against JEV through inhibition of protease, however, further investigations are required.Entities:
Keywords: Andrographis paniculata; Computational studies; In-vitro study; Japanese encephalitis virus; NS3 protease
Year: 2021 PMID: 34909671 PMCID: PMC8663989 DOI: 10.1016/j.crphar.2021.100043
Source DB: PubMed Journal: Curr Res Pharmacol Drug Discov ISSN: 2590-2571
Fig. 1Structure of andrographolide.
Fig. 2Interactions of andrographolide towards active site of NS3 helicase of JEV using Schrödinger 2019-3 suite.
Interactions of andrographolide against NS3 Helicase, NS5 and NS3 Protease along with their binding affinity and contacting amino acids residues.
| Phytoconstituent Name | Binding Affinity (Kcal/M) | Residues interacting with Ligand through H-Bonding | Closer Contact Residues |
|---|---|---|---|
| A. NS3 Helicase | |||
| Andrographolide | −5.7 | Val430, His488, Thr 290, Ser412 | Asp410, Ile411, Gln457, Ser454, Ala453, Thr451, Phe289, Ser429, Lys431, Leu444, Arg600 |
| Reference (Paritaprevir) | Glu155 | Leu49, Lys73, Glu74, Asp75, Trp83, Phe85, Asp86, Arg87, Lys88, Thr118, Leu120, Gly121, Glu122, Val13, Ala125, Ile147, Gly148, Leu149, Gly151, Asn152, Gly153, Val154, Leu156 | |
| Andrographolide | −4.5 | Asp146 | Glu111, Gly81, Cys82, Gly83, Arg84, Trp87, Ile147, Gly148, Ser150, Tyr220, Glu218, Asn216, Arg213 |
| Reference (S-Adenosyl-L-Homocysteine) | Ser46, Gly86, Asp131, Val132, Asp146 | Val55, Gly58, Trp87, Gly81, Cys82, Gly83, Gly85, Thr104, Hid110, Val130, Phe133, Ile147, Gly148 and Glu149 | |
| Andrographolide | −6.6 | Lys73, Asn152 | Arg76, Glu74, Lys73, Leu120, Val154, Gly153 |
| Reference (ST-610) | −5.5 | Thr290 and Asp410 | Phe289, Asp291, Ala364, Thr409, Ser412, Ser429, Val430, Lys431, Pro432, Thr451, Ala453, Ser454, Gln457, Arg458 and His488 |
Fig. 3Interactions of andrographolide towards active site of NS5 of JEV using Schrödinger 2019-3 suite.
Fig. 4Interactions of andrographolide towards active site of NS3 protease of JEV using Schrödinger 2019-3 suite.
ADMET profile of Andrographolide.
| Models | Andrographolide |
|---|---|
| Molecular weight (g/mol) | 336.42 |
| Log P O/W | 2.55 |
| GI absorption | High |
| BBB permeability | No |
| Caco-2 Permeability (log Papp in 10−6 cm/s) | 1.07 |
| Intestinal absorption (% Absorbed) | 95.357 |
| P-glycoprotein Substrate | No |
| P-glycoprotein 1 Inhibitor | No |
| P-glycoprotein 2 Inhibitor | No |
| VDss (human) (log L/kg) | −0.286 |
| BBB permeability (log BB) | −0.598 |
| CNS permeability (log PS) | −2.691 |
| CYP2D6 substrate | No |
| CYP3A4 substrate | Yes |
| CYP1A2 inhibitor | No |
| CYP2C19 inhibitor | No |
| CYP2C9 inhibitor | No |
| Total Clearance (log ml/min/kg) | 1.183 |
| Renal OCT2 substrate | No |
| AMES toxicity | No |
| Max. tolerated dose (human) (log mg/kg/day) | 0.128 |
| hERG I inhibitor | No |
| hERG II inhibitor | No |
| Hepatotoxicity | No |
| Skin Sensitisation | No |
| T. Pyriformis toxicity (log mM) | 0.491 |
| 5000 mg/kg | |
Caco-2 Permeability: >0.90 (High); Intestinal absorption: <30% (Poor absorption); Volume of distribution: >0.48 (High) & <0.15 (Low); Intestinal absorption: <30 (Poorly absorbed); Skin Permeability: >-2.5 (low); BBB permeability: >0.3 (crosses BBB), <-1 (poor); CNS permeability: >-2 (penetrable to CNS), <-3 (unable to penetrate CNS); T. Pyriformis toxicity (log mM): >-0.5 (Toxic).
Fig. 5Root Mean Square Deviation (RMSD) of backbone skeleton of protein NS3 protease and ligand as andrographolide using Desmond module of Schrödinger 2019-3 suite.
Fig. 6RMSF of andrographolide upon binding with the protein using Desmond module of Schrödinger 2019-3 suite.
Fig. 7Effect of molecular dynamics simulation on secondary structure elements (SSE) using Desmond module of Schrödinger 2019-3 suite.
Fig. 8Histogram indicating the interaction of andrographolide with NS3 protease in terms of interaction fraction using Desmond module of Schrödinger 2019-3 suite.